FDA expands Tzield approval to young children with stage 2 type 1 diabetes, aiming to delay insulin dependence

The U.S. FDA has authorised wider use of Tzield for children as young as 1 with stage 2 type 1 diabetes, offering potential to delay insulin treatment and highlight the importance of early diagnosis.

The U.S. Food and Drug Administration has widened the use of Tzield, allowing the immune therapy to be given to children as young as 1 with stage 2 type 1 diabetes, a move that could delay the need for insulin treatment and buy families valuable time. Diabetes Self-Management reported that the decision makes Tzield the first disease-modifying therapy approved for type 1 diabetes in this youngest age group.

The expansion is backed by interim data from the ongoing PETITE-T1D study, which is examining children under 8 with stage 2 disease. In the analysis cited by Diabetes Self-Management, nearly 90% of young participants treated with Tzield had not progressed to stage 3 diabetes over the study period, and only two children moved on to the insulin-requiring stage during a median follow-up of about 52 weeks. Researchers said the treatment was generally well tolerated.

Stage 2 type 1 diabetes is typically identified by the presence of diabetes-related autoantibodies and abnormal blood sugar levels before symptoms become severe enough to require insulin. According to the FDA, Tzield was first cleared for people aged 8 and older at high risk of developing type 1 diabetes, and its latest paediatric use extends the drug’s reach into an even earlier phase of the disease.

Clinicians and patient advocates say the approval also sharpens the case for earlier screening. Kimber Simmons, a paediatric endocrinologist at the University of Colorado Anschutz Medical Campus, told Diabetes Self-Management that young children at stage 2 can progress quickly and without warning. Archana R. Sadhu said delaying diagnosis can ease the daily burden on families, while Breakthrough T1D said the extra time could amount to about two years for some children. The FDA is also reviewing Tzield for possible use in children and teens who have already reached stage 3 disease, where symptoms are present and insulin is needed. The agency has warned that the drug can carry serious risks, including viral reactivation and low white blood cell counts.